Addex Therapeutics Ltd (SWX:ADXN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
0.0606
+0.0036 (6.32%)
Jun 6, 2025, 4:43 PM CET
-8.73%
Market Cap 5.96M
Revenue (ttm) 410.04K
Net Income (ttm) 7.06M
Shares Out 98.34M
EPS (ttm) 0.07
PE Ratio 0.84
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,666,130
Average Volume 209,279
Open 0.0600
Previous Close 0.0570
Day's Range 0.0598 - 0.0630
52-Week Range 0.0472 - 0.1095
Beta 1.99
RSI 60.75
Earnings Date May 19, 2025

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 2
Stock Exchange SIX Swiss Exchange
Ticker Symbol ADXN
Full Company Profile

Financial Performance

Financial Statements

News

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a port...

17 hours ago - GlobeNewsWire

Addex Convenes Annual General Meeting 2025

Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric mod...

3 days ago - GlobeNewsWire

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of no...

25 days ago - GlobeNewsWire

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...

5 weeks ago - GlobeNewsWire

Addex Therapeutics reports FY results

6 weeks ago - Seeking Alpha

Addex Reports Full Year 2024 Financial Results and Provides Corporate Update

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for devel...

6 weeks ago - GlobeNewsWire

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...

7 weeks ago - GlobeNewsWire

Addex to Present at the 2025 Swiss Equities Baader Conference

Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators...

5 months ago - GlobeNewsWire

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ...

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Adjustments

6 months ago - GuruFocus

Q3 2024 Addex Therapeutics Ltd Earnings Call Transcript

Q3 2024 Addex Therapeutics Ltd Earnings Call Transcript

6 months ago - GuruFocus

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board Director...

7 months ago - Seeking Alpha

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22...

7 months ago - GlobeNewsWire

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmac...

7 months ago - GlobeNewsWire

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and Strategic Developments

8 months ago - GuruFocus

Q2 2024 Addex Therapeutics Ltd Earnings Call Transcript

Q2 2024 Addex Therapeutics Ltd Earnings Call Transcript

8 months ago - GuruFocus

Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN) Q2 2024 Earnings Conference Call September 30, 2024 10:00 AM ETCompany ParticipantsTim Dyer - Co-Founder, Board...

8 months ago - Seeking Alpha

Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update

Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex sele...

8 months ago - GlobeNewsWire

Addex Therapeutics reports H1 results

9 months ago - Seeking Alpha

Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio...

9 months ago - GlobeNewsWire

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulato...

9 months ago - GlobeNewsWire

S&P 500 Edges Higher; American Woodmark Shares Slide

U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.2% on Tuesday. The Dow traded up 0.01% to 41,242.33 while the NASDAQ rose 0.24% to 17,768.84. The S&P 500 also ros...

10 months ago - Benzinga

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday. The Dow traded down 0.16% to 41,175.13 while the NASDAQ fell 0.03% to 17,720.68. The S&...

10 months ago - Benzinga